{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T02:55:01Z","timestamp":1764557701324,"version":"3.41.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Affiliated Hospital of Nanjing Medical University","award":["YNRCQN025"],"award-info":[{"award-number":["YNRCQN025"]}]},{"name":"Center for Healthy Development Research of Jiangsu Province","award":["JSHD2021004"],"award-info":[{"award-number":["JSHD2021004"]}]},{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"crossref","award":["H202002"],"award-info":[{"award-number":["H202002"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ibrutinib and zanubrutinib are Bruton tyrosine kinase inhibitors used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Dihydroxydiol ibrutinib (DHI) is an active metabolite of the drug. A liquid chromatography\u2013tandem mass spectrometry method was developed to detect ibrutinib, DHI, and zanubrutinib in human plasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The method involved a protein precipitation step, followed by chromatographic separation using a gradient of 10 mM ammonium acetate (containing 0.1% formic acid)\u2013acetonitrile. Ibrutinib-d5 was used as an internal standard. Analytes were separated within 6.5 minutes. The optimized multiple reaction monitoring transitions of <jats:italic toggle=\"yes\">m\/z<\/jats:italic> 441.1 \u2192 304.2, 475.2 \u2192 304.2, 472.2 \u2192 455.2, and 446.2 \u2192 309.2 were selected to inspect ibrutinib, DHI, zanubrutinib, and the internal standards in positive ion mode.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The validated curve ranges included 0.200\u2013800, 0.500\u2013500, and 1.00\u20131000 ng\/mL for ibrutinib, DHI, and zanubrutinib, respectively. The precisions of the lower limit of quantification of samples were below 15.5%, the precisions of the other level samples were below 11.4%, and the accuracies were between \u22128.6% and 8.4%. The matrix effect and extraction recovery of all compounds ranged between 97.6%\u2013109.0% and 93.9%\u2013105.2%, respectively. The selectivity, accuracy, precision, matrix effect, and extraction recovery results were acceptable according to international method validation guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A simple and rapid method was developed and validated in this study. This method was used to analyze plasma concentrations of ibrutinib and zanubrutinib in patients with mantle cell lymphoma, chronic lymphocytic leukemia\/small lymphocytic lymphoma, or diffuse large B-cell lymphoma. The selected patients were aged between 44 and 74 years.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001190","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T04:01:05Z","timestamp":1711512065000},"page":"634-641","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography\u2013Mass Spectrometry\/Mass Spectrometry"],"prefix":"10.1097","volume":"46","author":[{"given":"Yu-Jiao","family":"Guo","sequence":"first","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Tian","family":"Du","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Long","family":"Chen","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Ning","family":"Sun","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and"},{"name":"School of Pharmacy, Nanjing Medical University, Nanjing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"R2-20250603","first-page":"5","article-title":"Non-Hodgkin's lymphoma","volume":"14","author":"Pearce","year":"2016","journal-title":"Nurs Stand"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-13150-4_1","article-title":"Epidemiology and etiology of non-Hodgkin lymphoma","volume":"165","author":"Chiu","year":"2015","journal-title":"Cancer Treat Res"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"119419","DOI":"10.1016\/j.saa.2020.119419","article-title":"Three efficient chemometrics assisted fluorimetric detection methods for interference-free, rapid, and simultaneous determination of ibrutinib and pralatrexate in various complicated biological fluids","volume":"252","author":"Chang","year":"2021","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch Pharm Res"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"e00870","DOI":"10.1002\/prp2.870","article-title":"In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor","volume":"9","author":"Zhang","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur J Cancer"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Br\u00fcggemann","year":"2022","journal-title":"Lancet Haematol"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/00498254.2021.1969481","article-title":"Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies","volume":"51","author":"Huang","year":"2021","journal-title":"Xenobiotica"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"120450","DOI":"10.1016\/j.talanta.2019.120450","article-title":"Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring","volume":"208","author":"Koller","year":"2020","journal-title":"Talanta"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/FTD.0000000000000825","article-title":"Simultaneous quantification of BCR-ABL and Bruton tyrosine kinase inhibitors in dried plasma spots and its application to clinical sample analysis","volume":"43","author":"Mukai","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"121928","DOI":"10.1016\/j.jchromb.2019.121928","article-title":"Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma","volume":"1137","author":"Mukai","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"e5124","DOI":"10.1002\/bmc.5124","article-title":"High-throughput liquid chromatography\/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma","volume":"35","author":"Hirasawa","year":"2021","journal-title":"Biomed Chromatogr"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"122140","DOI":"10.1016\/j.talanta.2021.122140","article-title":"Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS\/MS method","volume":"226","author":"Verougstraete","year":"2021","journal-title":"Talanta"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"114923","DOI":"10.1016\/j.jpba.2022.114923","article-title":"High-throughput salting-out assisted liquid-liquid extraction using a 3D printed device and its application in the quantification of ibrutinib and its metabolite PCI-45227 in human serum","volume":"219","author":"\u00c9csiov\u00e1","year":"2022","journal-title":"J Pharm Biomed Anal"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:11:13Z","timestamp":1748970673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001190","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"2023-01-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}